BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies.

The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer.

It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers.

In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform.

The company was founded in 2010 and is headquartered in New York, New York.